Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 4, 2013, Pages 753-760

  Ragnum, Harald Bull ^a   Røe, Kathrine ^a,b   Holm, Ruth ^a   Vlatkovic, Ljiljana ^a   Nesland, Jahn Marthin ^a,c   Aarnes, Eva Katrine ^a   Ree, Anne Hansen ^b,c   Flatmark, Kjersti ^a   Seierstad, Therese ^a,d   Lilleby, Wolfgang ^a   Lyng, Heidi ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; DIFFERENTIALLY EXPRESSED GENE; GENE EXPRESSION PROFILES; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOHISTOCHEMISTRY; METHODS AND MATERIALS; PROSTATE CANCER CELLS; PROTEIN EXPRESSIONS;

BIOLOGICAL MATERIALS; CELL CULTURE; DISEASES; METABOLISM; PHYSIOLOGY; PROTEINS; TUMORS;

GENE EXPRESSION;

ANDROGEN RECEPTOR; BICALUTAMIDE; GLUCOSE TRANSPORTER 1; GLYCOLYTIC ENZYME; GOSERELIN; HYPOXIA INDUCIBLE FACTOR 1; MONOSACCHARIDE; PIMONIDAZOLE; PROSTATE SPECIFIC ANTIGEN; PROTEIN HK2; PROTEIN PFKFB3; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLEASON SCORE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRESS; TUMOR REGRESSION; TUMOR XENOGRAFT; UPREGULATION;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DOWN-REGULATION; GENE EXPRESSION PROFILING; GOSERELIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INDUCTION CHEMOTHERAPY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; RECEPTORS, ANDROGEN; STRESS, PHYSIOLOGICAL; TOSYL COMPOUNDS; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84886091179     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.07.023     Document Type: Article

References (32)

1. M. Milosevic, P. Warde, and C. Menard Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer Clin Cancer Res 18 2012 2108 2114
2. A. Turaka, M.K. Buyyounouski, and A.L. Hanlon Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results Int J Radiat Oncol Biol Phys 82 2012 e433 e439
3. C.E. Massie, A. Lynch, and A. Ramos-Montoya The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis EMBO J 30 2011 2719 2733
4. P. Westin, P. Stattin, and J.E. Damber Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors Am J Pathol 146 1995 1368 1375
5. F.Y. Feng, K. Blas, and K. Olson Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer Int J Radiat Oncol Biol Phys 86 2013 64 71
6. Z.S. Zumsteg, D.E. Spratt, and X. Pei Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy Int J Radiat Oncol Biol Phys 85 2013 1012 1017
7. M. Milosevic, P. Chung, and C. Parker Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response Cancer Res 67 2007 6022 6025
8. N. Chan, M. Milosevic, and R.G. Bristow Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies Future Oncol 3 2007 329 341
9. F.L. Al-Ubaidi, N. Schultz, and L. Egevad Castration therapy of prostate cancer results in downregulation of HIF-1alpha levels Int J Radiat Oncol Biol Phys 82 2012 1243 1248
10. M.M. Green, C.T. Hiley, and J.H. Shanks Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome Int J Radiat Oncol Biol Phys 67 2007 84 90
11. R. Vergis, C.M. Corbishley, and A.R. Norman Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study Lancet Oncol 9 2008 342 351
12. N.J. Mabjeesh, M.T. Willard, and C.E. Frederickson Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells Clin Cancer Res 9 2003 2416 2425
13. R. Toivanen, R.A. Taylor, and D.W. Pook Breaking through a roadblock in prostate cancer research: an update on human model systems J Steroid Biochem Mol Biol 131 2012 122 131
14. K. Roe, L.T. Mikalsen, and A.J. van der Kogel Vascular responses to radiotherapy and androgen deprivation therapy in experimental prostate cancer Radiat Oncol 7 2012 75
15. M.A. Wainstein, F. He, and D. Robinson CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma Cancer Res 54 1994 6049 6052
16. V.P. Montecinos, A. Godoy, and J. Hinklin Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma PLoS One 7 2012 e29623
17. K. Roe, A. Bratland, and L. Vlatkovic Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer PLoS One 8 2013 e63723
18. N. Sampson, H. Neuwirt, and M. Puhr In vitro model systems to study androgen receptor signaling in prostate cancer Endocr Relat Cancer 20 2013 R49 R64
19. W. Parson, R. Kirchebner, and R. Muhlmann Cancer cell line identification by short tandem repeat profiling: power and limitations FASEB J 19 2005 434 436
20. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
21. C. Halle, M. Lando, and D.H. Svendsrud Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer Clin Cancer Res 17 2011 5501 5512
22. D.R. Mole, C. Blancher, and R.R. Copley Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts J Biol Chem 284 2009 16767 16775
23. X. Xia, M.E. Lemieux, and W. Li Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis Proc Natl Acad Sci U S A 106 2009 4260 4265
24. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 25 2001 402 408
25. W. Huang da, B.T. Sherman, and R.A. Lempicki Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nat Protoc 4 2009 44 57
26. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Statist Soc B 57 1995 289 300
27. C.A. Heinlein, and C. Chang Androgen receptor in prostate cancer Endocr Rev 25 2004 276 308
28. M.L. Mohler, C.C. Coss, and C.B. Duke III Androgen receptor antagonists: a patent review (2008-2011) Expert Opin Ther Pat 22 2012 541 565
29. K. Horii, Y. Suzuki, and Y. Kondo Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells Mol Cancer Res 5 2007 383 391
30. K.S. Kimbro, and J.W. Simons Hypoxia-inducible factor-1 in human breast and prostate cancer Endocr Relat Cancer 13 2006 739 749
31. M.G. Vander Heiden, L.C. Cantley, and C.B. Thompson Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 2009 1029 1033
32. D. Tondera, A. Santel, and R. Schwarzer Knockdown of MTP18, a novel phosphatidylinositol 3-kinase-dependent protein, affects mitochondrial morphology and induces apoptosis J Biol Chem 279 2004 31544 31555